Gene Expression Signatures of a Preclinical Mouse Model during Colorectal Cancer Progression under Low-Dose Metronomic Chemotherapy.
Hung Ho-XuanGerhard LehmannPetar GlazarFoivos GypasNorbert EichnerKevin HeizlerHans Jürgen SchlittMihaela ZavolanNikolaus RajewskyGunter MeisterChristina HacklPublished in: Cancers (2020)
Understanding the molecular signatures of colorectal cancer progression under chemotherapeutic treatment will be crucial for the success of future therapy improvements. Here, we used a xenograft-based mouse model to investigate, how whole transcriptome signatures change during metastatic colorectal cancer progression and how such signatures are affected by LDM chemotherapy using RNA sequencing. We characterized mRNAs as well as non-coding RNAs such as microRNAs, long non-coding RNAs and circular RNAs in colorectal-cancer bearing mice with or without LDM chemotherapy. Furthermore, we found that circZNF609 functions as oncogene, since over-expression studies lead to an increased tumor growth while specific knock down results in smaller tumors. Our data represent novel insights into the relevance of non-coding and circRNAs in colorectal cancer and provide a comprehensive resource of gene expression changes in primary tumors and metastases. In addition, we present candidate genes that could be important modulators for successful LDM chemotherapy.
Keyphrases
- gene expression
- mouse model
- genome wide
- long non coding rna
- locally advanced
- low dose
- poor prognosis
- dna methylation
- metastatic colorectal cancer
- single cell
- squamous cell carcinoma
- type diabetes
- skeletal muscle
- electronic health record
- radiation therapy
- rna seq
- insulin resistance
- mesenchymal stem cells
- current status
- case control
- binding protein
- data analysis
- replacement therapy